Phase I/II Study of Carfilzomib, Melphalan and Prednisone for Elderly Patients with Newly Diagnosed Multiple Myeloma


Phase I/II Study of Carfilzomib, Melphalan and Prednisone for Elderly Patients with Newly Diagnosed Multiple Myeloma
Slides from presentations at ASCO 2013/EHA 2013 and transcribed comments from a recent interview with Antonio Palumbo, MD (8/20/13)

Touzeau C et al. Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial. Proc ASCO 2013;Abstract 8513.

Moreau P et al. CMP — carfilzomib plus melphalan-prednisone (MP) — in elderly patients (Pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (PH) I/II trial. Proc EHA 2013;Abstract P224.

Dr Palumbo is Chief of the Myeloma Unit in the University of Torino’s Division of Hematology in Torino, Italy.